arrow
A

Alyx B. Porter

Mayo Clinic
H指数:20
被引数:1,495

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Genotype-first analysis redefines autosomal dominant LZTR1-related disorders susceptibility architecture

基于基因型分析重新定义常染色体显性LZTR1相关疾病的易感架构

2026-09-160
OAAI
From barrier to bridge: a scoping review on the methods, clinical efficacy, and safety of blood–brain barrier disruption in treating high-grade glioma

从屏障到桥梁:关于血脑屏障破坏在治疗高级别胶质瘤中的方法、临床疗效和安全性的范围综述

2026-04-010
PRE
Pembrolizumab efficacy in recurrent adult-type diffuse gliomas

帕博利珠单抗在复发成人型弥漫性胶质瘤中的疗效

2025-11-010
OAAI
Clinical utility of RANO 2.0 for response assessment to immunotherapy in recurrent gliomas

RANO 2.0在复发性胶质瘤免疫治疗反应评估中的临床应用价值

2025-11-010
PRE
WSD0922-FU THERAPY IN PATIENTS WITH EGFR MUTANT GLIOBLASTOMA - UPDATES FROM THE DOSE EXPANSION COHORTS OF A FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL (MC1914)

WSD0922-FU疗法在EGFR突变型胶质母细胞瘤患者中的应用——来自一项首次人体I期临床试验(MC1914)剂量扩展队列的更新信息

2025-11-010
OAAI
RELATIONSHIPS BETWEEN LYMPHOCYTE COUNTS AND CLINICAL OUTCOMES IN PATIENTS WITH GLIOMAS TREATED WITH PEMBROLIZUMAB

胶质瘤患者接受帕博利珠单抗治疗后淋巴细胞计数与临床结局的关系

2025-11-010
OAAI
Radiation Therapy for WHO Grade 4 Adult-Type Diffuse Glioma: An ASTRO Clinical Practice Guideline

WHO四级成人型弥漫性胶质瘤的放射治疗:ASTRO临床实践指南

2025-06-250
PRE
Predicting therapeutic clinical trial enrollment for adult patients with low- and high-grade glioma using supervised machine learning

使用监督式机器学习预测低级别和高级别胶质瘤成年患者的治疗性临床试验入组

2025-01-010
OA
INDIVIDUALIZED TUMOR-SPECIFIC AMPLIFIED DNA JUNCTIONS FOR PLASMA-BASED MONITORING IN PATIENTS WITH HIGH-GRADE GLIOMAS
2024-11-110
PRE
Clinical features and outcomes in primary nervous system histiocytic neoplasms

原发性神经系统组织细胞肿瘤的临床特征和预后

2024-06-201
OAAI
Integrated molecular and multiparametric MRI mapping of high-grade glioma identifies regional biologic signatures
2023-09-285
OAAI